Awkan’s Chief Research Officer Prof David Nutt will chair both advisory boards with Prof Stephen Husbands, Prof Harriet De Wit, and Prof Kevin Fone joining the preclinical advisory board. TORONTO,…

Broadening of intellectual property portfolio for these two NCEs clearly defines development pathway for the next generation of psychedelic medicines to treat addiction TORONTO, CANADA, 28 June 2021 – Awakn…

PROF. NUTT WILL DRIVE PROGRESSION OF A PIPELINE OF NEW PSYCHEDELIC MEDICINES, HELPING TO DEFINE A CLEAR DEVELOPMENT PATHWAY TO TREAT ADDICTION THROUGH PSYCHEDELIC MEDICINES TORONTO, CANADA, 24 June 2021…

TORONTO, Ontario, June 23, 2021 – Awakn Life Sciences Corp. (“Awakn” or the “Company”) a biotechnology company with clinical operations developing, and delivering psychedelic medicines to treat Addiction, is pleased…

Vancouver, B.C., June 17, 2021 – Further to its press release date May 17, 2021, Awakn Life Sciences Corp. (formerly 1169082 B.C. Ltd.) (the “Company”) is pleased to announce that…

TORONTO, Ontario, June 10, 2021 – Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat Addiction, announced today that Anthony…

Vancouver, B.C., June 8, 2021 – 1169082 B.C. Ltd. (the “Company”) and Awakn Life Sciences Inc. (“Awakn”), are pleased to announce the closing of the previously announced brokered private placement…

Vancouver, British Columbia–(Newsfile Corp. – May 17, 2021) – 1169082 B.C. Ltd. (the “Company”) is pleased to announce that it has entered into a definitive binding amalgamation agreement dated May 13, 2021…

Defining clear development pathway for next generation of psychedelic medicines to treat addiction Awakn announces today the initiation of a new chemical entity (NCE) development program to strengthen Awakn’s pipeline…

Awakn announces the appointment of Stephen Page and Professor John Papastergiou as independent non-executive directors to the company’s Board of Directors. Adding significant pharmaceutical and healthcare sector experience and independent…

First project to use advanced analytics to explore identity shifts in alcohol addiction Awakn launches ‘Awakn Digital’, a new unit focused on using advanced analytics to improve the effectiveness of…

Prof. Nutt appointed Head of Research to Lead Awakn’s Next-Gen Psychedelic Molecule Development Awakn Life Sciences announces the acquisition of significant proprietary research data on next generation candidate MDMA and…